For someone who has lost their sight, detecting even the outline of an object or finding a doorway can be an extraordinary achievement. Now, scientists have helped people with advanced blindness do just that — not by repairing their damaged light-sensing cells, but by teaching other cells in their eyes to respond to light.
In a clinical trial involving ten patients, an experimental gene therapy combined with high-tech goggles improved light sensitivity in seven participants.
Six of them experienced clinically meaningful improvements, while several regained limited abilities to detect objects and navigate visual surroundings. The findings suggest that scientists may be able to restore some visual function even after the cells normally responsible for sight have largely disappeared.
A clever workaround for a devastating disease
The patients had retinitis pigmentosa, a group of inherited diseases that gradually destroy the retina’s photoreceptors — the specialized cells that detect light. An estimated 1.5 million people worldwide suffer from this disease.
In a healthy eye, photoreceptors convert incoming light into electrical signals. Other cells in the retina process those signals before passing them to the brain, which turns them into the images we see.
But in retinitis pigmentosa, the photoreceptors progressively break down. Patients first struggle to see at night; then they lose their peripheral vision. Eventually, they become severely visually impaired or even blind.
There’s another problem with the disease. It can result from mutations in many different genes. That makes developing a universal treatment particularly difficult. Plus, even if scientists correct the mutation responsible for a patient’s condition, they cannot necessarily bring back photoreceptors that have already died.
The international research team, led by José-Alain Sahel of the University of Pittsburgh and Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel in Switzerland, took a different approach.
Repurposing cells
Rather than trying to resurrect lost photoreceptors, the scientists targeted retinal ganglion cells. These nerve cells normally receive processed visual information and transmit it toward the brain. Importantly, many ganglion cells survive even in advanced retinitis pigmentosa.
The researchers reasoned that if they could make these surviving cells sensitive to light, they might bypass the damaged part of the retina altogether.
To do that, they turned to a technology called optogenetics, which uses genes for light-sensitive proteins to make cells respond to illumination.
The team injected a modified, non-disease-causing virus into one eye of each patient. The virus carried genetic instructions for a protein called ChrimsonR, which acts as a light-activated switch. Once the retinal ganglion cells produced this protein, they could respond directly to specially delivered light signals.
But the injection was only half the treatment.
Special goggles
Patients also wore specialized goggles equipped with a camera and light projector. The goggles captured the surrounding scene, processed the visual information, and projected patterns of light onto the treated retina.
Importantly, the treatment was safe in all 10 participants, the researchers note. This was part of a phase 1/2 clinical trial whose primary target was to assess safety. But the researchers also measured changes in light sensitivity and investigated whether patients could use their newfound visual perception to complete practical tasks.
The results were encouraging.
Seven of the ten participants showed improved light sensitivity when using the goggles. The improvement ranged from twice their previous sensitivity to more than 60 times, depending on the participant.
The result wasn’t normal vision. Instead, patients could perceive simplified visual information that had previously been inaccessible to them. It’s something that could make patients’ lives significantly better. For a person with profound vision loss, even these seemingly modest abilities could offer valuable information about their surroundings.
A surprisingly connection to algae and a Nobel Prize
The latest findings also build on a remarkable result reported in 2021. In that earlier study, published in Nature Medicine, the same research collaboration described a blind patient who could perceive, locate, count, and touch objects after receiving optogenetic therapy.
But the light-sensitive proteins used in optogenetics trace their origins to microorganisms, including green algae.
Certain algae possess proteins called channelrhodopsins that help them respond to light. These proteins act like tiny gates in cell membranes. When illuminated, they open and allow electrically charged particles to pass through, changing the cell’s electrical activity.
Scientists eventually realized that they could introduce genes for these proteins into other cells, including neurons, and use light to control their activity. The discovery helped launch optogenetics, which transformed neuroscience by allowing researchers to activate selected nerve cells with extraordinary precision.
On October 5, 2026, just two days before the new study appeared, the Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for pioneering work that made optogenetics possible.
What began as fundamental research into light-sensitive biological molecules has now helped produce an experimental treatment for people who have lost their natural light-detecting cells.
Together, the gene therapy and goggles created an alternative route for visual information to reach the brain. There’s still a long way to go before actually returning vision to patients, but the work is encouraging.
Study: Sahel, J.-A., Futterknecht, S., et al. (2026). Optogenetic Therapy for Restoring Aspects of Visual Function. New England Journal of Medicine. DOI: 10.1056/NEJMoa2602215.
